Understanding how human immune cells interact with bacterial infections
Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens
This study looks at how our immune cells fight off bacterial infections to see why some bacteria can escape our defenses and cause illness.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Hamilton, Montana) |
| Trial ID | NCT00339287 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the interactions between human phagocytic cells, such as neutrophils, and bacterial pathogens. It focuses on identifying mechanisms that allow bacteria to evade the immune response and contribute to disease. The study employs advanced genomics and proteomics techniques to analyze phagocyte responses and the characteristics of various pathogens. By understanding these interactions, the research seeks to shed light on the pathophysiology of inflammatory disorders.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults aged 18 and older with no known medical problems.
Not a fit: Patients with genetic defects that impair phagocyte function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for enhancing immune responses against bacterial infections.
How similar studies have performed: Other studies have shown success in understanding immune responses to pathogens, making this approach promising yet still requiring further exploration.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION \& EXCLUSION CRITERIA: Volunteers will be selected from a healthy adult population, 18 years of age or older, with no known medical problems and will generally be NIH employees working at Rocky Mountain Laboratories (RML) or within the community of Hamilton, MT. No race or gender is excluded from the donor pool and reflects the diversity of the community and that of the employees at RML. The specific criteria for eligibility are as follows: * Subjects must fit the definition of "healthy adults" as assessed by the medical/health screening evaluations, and willing to have blood and/or tissue samples stored for future use. * Inasmuch as all subjects are RML employees, they will be 18 years of age or older. * Children are excluded. * Pregnant women will be identified by verbal history and are not eligible to donate blood for this protocol. * The study population will be all-inclusive except in certain instances where individuals possess genetic defects that impair phagocyte function (e.g., myeloperoxidase-deficiency) or have altered phagocyte function due to outside influences such as recent bacterial or viral infection. * Individuals below the normal hematocrit and hemoglobin ranges will be excluded from the protocol.
Where this trial is running
Hamilton, Montana
- NIAID, Rocky Mountain Laboratories — Hamilton, Montana, United States (Recruiting)
Study contacts
- Principal investigator: Frank R De Leo, Ph.D. — National Institute of Allergy and Infectious Diseases (NIAID)
- Study coordinator: Frank R De Leo, Ph.D.
- Email: fdeleo@niaid.nih.gov
- Phone: (406) 363-9448
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.